Ultralife Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Ultralife wird ein Gewinn- und Umsatzwachstum von 43.8% bzw. 25.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 43.3% pro Jahr wachsen soll.

Wichtige Informationen

43.8%

Wachstumsrate der Gewinne

43.3%

EPS-Wachstumsrate

Electrical Gewinnwachstum	18.4%
Wachstumsrate der Einnahmen	25.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

These 4 Measures Indicate That Ultralife (NASDAQ:ULBI) Is Using Debt Reasonably Well

Apr 16

Slowing Rates Of Return At Ultralife (NASDAQ:ULBI) Leave Little Room For Excitement

Mar 14

Insufficient Growth At Ultralife Corporation (NASDAQ:ULBI) Hampers Share Price

Feb 11

Is Now An Opportune Moment To Examine Ultralife Corporation (NASDAQ:ULBI)?

Oct 26

Ultralife (NASDAQ:ULBI) May Have Issues Allocating Its Capital

Sep 22

Ultralife (NASDAQ:ULBI) Takes On Some Risk With Its Use Of Debt

Jun 08

Ultralife (NASDAQ:ULBI) Is Carrying A Fair Bit Of Debt

Sep 27

Ultralife secures $7.5M communications systems contract

Sep 22

Ultralife receives $4.6M communications systems VAA order

Jul 26

Does Ultralife (NASDAQ:ULBI) Have A Healthy Balance Sheet?

Apr 15

We Think Ultralife Corporation's (NASDAQ:ULBI) CEO Compensation Package Needs To Be Put Under A Microscope

Jul 15

Is Ultralife Corporation (NASDAQ:ULBI) Potentially Undervalued?

Apr 14

The Trends At Ultralife (NASDAQ:ULBI) That You Should Know About

Mar 09

Ultralife Corporation's (NASDAQ:ULBI) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 18

Ultralife reports Q4 results

Feb 04

If You Had Bought Ultralife (NASDAQ:ULBI) Stock Five Years Ago, You Could Pocket A 17% Gain Today

Feb 03

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:ULBI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	219	14	N/A	N/A	1
12/31/2024	161	8	N/A	N/A	1
9/30/2024	165	9	14	16	N/A
6/30/2024	169	10	8	10	N/A
3/31/2024	169	10	1	3	N/A
12/31/2023	159	7	-1	2	N/A
9/30/2023	150	4	0	2	N/A
6/30/2023	144	3	0	3	N/A
3/31/2023	133	0	-1	1	N/A
12/31/2022	132	0	-3	-1	N/A
9/30/2022	119	-1	-10	-8	N/A
6/30/2022	108	-1	-8	-6	N/A
3/31/2022	103	-1	-5	-3	N/A
12/31/2021	98	0	2	4	N/A
9/30/2021	103	3	5	9	N/A
6/30/2021	106	4	17	20	N/A
3/31/2021	108	5	23	26	N/A
12/31/2020	108	5	19	22	N/A
9/30/2020	110	5	20	23	N/A
6/30/2020	113	5	6	10	N/A
3/31/2020	114	6	-7	-3	N/A
12/31/2019	107	5	-9	-3	N/A
9/29/2019	97	23	-9	-1	N/A
6/30/2019	90	24	-2	5	N/A
3/31/2019	83	23	5	11	N/A
12/31/2018	87	25	7	11	N/A
9/30/2018	89	9	9	11	N/A
7/1/2018	89	9	N/A	5	N/A
4/1/2018	87	8	N/A	4	N/A
12/31/2017	86	8	N/A	7	N/A
10/1/2017	85	6	N/A	8	N/A
7/2/2017	83	6	N/A	12	N/A
4/2/2017	84	5	N/A	13	N/A
12/31/2016	82	4	N/A	8	N/A
9/25/2016	80	2	N/A	5	N/A
6/26/2016	79	2	N/A	3	N/A
3/27/2016	78	3	N/A	3	N/A
12/31/2015	76	3	N/A	9	N/A
9/27/2015	77	3	N/A	11	N/A
6/28/2015	74	2	N/A	7	N/A
3/29/2015	70	0	N/A	4	N/A
12/31/2014	66	-2	N/A	4	N/A
9/28/2014	67	-3	N/A	6	N/A
6/29/2014	71	-2	N/A	6	N/A
3/30/2014	73	-2	N/A	10	N/A
12/31/2013	79	-1	N/A	7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ULBIDas prognostizierte Gewinnwachstum (43.8% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: ULBIDie Erträge des Unternehmens (43.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: ULBIEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: ULBIDie Einnahmen des Unternehmens (25.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: ULBIDie Einnahmen des Unternehmens (25.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ULBI in 3 Jahren voraussichtlich hoch sein wird

Ultralife Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.7% to US$12.00

Consensus revenue estimates increase by 12%

Price target increased to US$12.00

Consensus revenue estimates fall by 14%

Recent updates

Ultralife Corporation to Report Q3, 2024 Results on Nov 08, 2024

Ultralife Corporation (NasdaqGM:ULBI) signed a stock purchase agreement to acquire Electrochem Solutions, Inc. from Integer Holdings Corporation (NYSE:ITGR) for $50 million.

Should You Think About Buying Ultralife Corporation (NASDAQ:ULBI) Now?

Ultralife: I Bought The Dip; Here Comes The Growth

Ultralife's (NASDAQ:ULBI) Earnings Are Weaker Than They Seem

Ultralife Corporation to Report Q2, 2024 Results on Jul 25, 2024

Ultralife Corporation Is Attractive Here

Ultralife Corporation, Annual General Meeting, Jul 16, 2024

Investor sentiment improves as stock rises 17%

Price target decreased by 7.7% to US$12.00

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ultralife Corporation: Ready To Surge

These 4 Measures Indicate That Ultralife (NASDAQ:ULBI) Is Using Debt Reasonably Well

Ultralife Corporation to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: US$0.44 (vs US$0.007 loss in FY 2022)

Slowing Rates Of Return At Ultralife (NASDAQ:ULBI) Leave Little Room For Excitement

Full year 2023 earnings released: EPS: US$0.44 (vs US$0.007 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Insufficient Growth At Ultralife Corporation (NASDAQ:ULBI) Hampers Share Price

New major risk - Revenue and earnings growth

Ultralife Corporation to Report Q4, 2023 Results on Feb 15, 2024

Independent Chairman recently bought US$111k worth of stock

Independent Chairman recently bought US$181k worth of stock

Independent Chairman recently bought US$99k worth of stock

Investor sentiment deteriorates as stock falls 19%

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Is Now An Opportune Moment To Examine Ultralife Corporation (NASDAQ:ULBI)?

Ultralife Corporation to Report Q3, 2023 Results on Oct 26, 2023

Investor sentiment improves as stock rises 18%

Ultralife (NASDAQ:ULBI) May Have Issues Allocating Its Capital

Independent Chairman recently bought US$112k worth of stock

Investor sentiment improves as stock rises 27%

Consensus revenue estimates increase by 12%

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ultralife Corporation to Report Q2, 2023 Results on Jul 27, 2023

Independent Chairman recently bought US$398k worth of stock

Ultralife (NASDAQ:ULBI) Takes On Some Risk With Its Use Of Debt

Independent Chairman recently bought US$146k worth of stock

Ultralife Corporation, Annual General Meeting, Jul 19, 2023

Independent Chairman recently bought US$117k worth of stock

Full year 2022 earnings released: US$0.007 loss per share (vs US$0.015 loss in FY 2021)

Independent Chairman recently bought US$122k worth of stock

Full year 2022 earnings released: US$0.007 loss per share (vs US$0.015 loss in FY 2021)

Independent Chairman recently bought US$279k worth of stock

Ultralife Corporation Announces Executive Changes

Price target increased to US$12.00

Insufficient new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Ultralife Corporation to Report Q3, 2022 Results on Oct 27, 2022

Ultralife (NASDAQ:ULBI) Is Carrying A Fair Bit Of Debt

Ultralife secures $7.5M communications systems contract

Independent Chairman recently bought US$158k worth of stock

Independent Chairman recently bought US$467k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ultralife receives $4.6M communications systems VAA order

Ultralife Corporation to Report Q2, 2022 Results on Jul 28, 2022

Independent Chairman recently bought US$219k worth of stock

Ultralife Corporation, Annual General Meeting, Jul 20, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Ultralife Corporation to Report Q1, 2022 Results on Apr 28, 2022

Does Ultralife (NASDAQ:ULBI) Have A Healthy Balance Sheet?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Chairman recently bought US$245k worth of stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 14%

Investor sentiment improved over the past week

Ultralife Corporation (NasdaqGM:ULBI) acquired Excell Battery Company for $23.5 million.

Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.026 profit in 3Q 2020)

Independent Chairman recently bought US$199k worth of stock